HOLD the core position; defer trimming until confirmed breakdown below $268 or next earnings catalyst resolves the execution overhang; reject the trader's current plan

• Technical indicators have shifted to neutral-tactical-bullish: MACD fresh bullish crossover, RSI recovered from 25 to 55, price reclaimed 10 EMA and 50 SMA, 50 SMA collapsed 14%
• Price is 7% below the 200 SMA; MCD is up meaningfully from July 23rd low of $262.80, held at lower Bollinger band, found buyers at VWMA, consolidating in tightening range
• Valuation is reasonable-to-cheap: Forward P/E 19.7, operating margin 46.5%, net margin 31.7%, ROA 13.25%, free cash flow $6.26 billion, beta 0.42; PEG ratio of 2.54 is unreliable for mature cash-generative businesses
• Dividend yield of 2.71% (nearly double S&P 500 yield) with 10 consecutive years of dividend growth; selling forfeits yield buffer at the worst moment
• Macro setup favors defensives: Fed rates on hold at 86% probability of no cuts, recession odds at 8%, restrictive real yields; MCD's 0.42 beta is the hedge against further downside
• Competitive position improving: RBI is wounded animal under activist pressure, Wendy's cut dividend, competitive set collectively weaker than five years ago
• Trader's stop at $296 ($20 above current $275.70 close) forces selling into strength if stock rallies, flipping the asymmetric risk-reward against the trader
• ATR of 5.73 and average daily ranges of $11-14 make limit orders at $278 vulnerable to poor fills in volatile conditions
• Q2 fundamentals are records: Revenue $7.10 billion (highest in five-quarter window), net income $2.36 billion (highest), buyback pace accelerated to $856 million
• Overhead resistance identified at $278-$296; selling into base formation at these levels is selling low before recovery completes
• Conservative trim approach: reduce on weakness below $270 into support zone at $261-262, where risk-reward of reloading favors the patient buyer
• Do not sell on confirmed momentum turn at neutral RSI; selling into 200 SMA reclaim historically marks the start of multi-month rally

→ vs aggressive: Technical doom narrative is unsupported—their own technical analysis report called it neutral-tactical-bullish, not bearish; MACD crossover, RSI recovery, and price reclamation of moving averages contradict the bearish thesis

→ vs aggressive: Valuation argument is intellectually lazy—Forward P/E of 19.7 with 46.5% operating margin, 31.7% net margin, 13.25% ROA, $6.26 billion FCF, and 0.42 beta is not expensive; applying hypergrowth PEG framework to a serial compounder is a category error

→ vs aggressive: Bear market rally characterization ignores that MCD held at lower Bollinger band, found buyers at VWMA, and is forming a base—base formations into overhead resistance are not the action of a stock in free fall

→ vs aggressive: Macro rotation thesis is premature—the generalizing of 'disinflation means cyclicals outperform defensives' applies to early-cycle recoveries, not late-cycle with Fed on hold at 86% no-cut probability and restrictive real yields

→ vs aggressive: Q2 'easy comps' dismissal is half-truth—revenue $7.10 billion and net income $2.36 billion are the highest in the five-quarter window; accelerated buyback pace of $856 million shows management confidence

→ vs neutral: Trader's stop placement at $296 is counterproductive—$20 above current $275.70 close means getting stopped out on a rally through overhead resistance, locking in losses on a name that just reclaimed its long-term trend

→ vs neutral: Tranche scaling at $278-280, $282-285, and $296 asks the market to cooperate with three orderly price levels that the stock will likely rip through on any sustained break above $296 due to short covering squeeze

→ vs neutral: Entry for trim at $278.50 is at short-term resistance—the conservative move is to trim on weakness below $270 into $261-262 support zone where reload risk-reward is favorable, not at resistance

→ vs neutral: Current plan structure is contradictory—holding a position you plan to trim at resistance while using a stop that triggers on the very momentum signal that should encourage holding

MODERATE TRIM (20-30% position reduction at Bollinger upper band ~$278.70; single tranche; re-evaluate on close below $268; abandon trim if stock closes above $290 on volume)

• 50 SMA collapsed 14% in four months; 200 SMA sloping down; price 7% below dominant long-term trend — these are dominant structural forces, not noise
• Q2 revenue of $7.10B and net income of $2.36B were both highest in the five-quarter window; buybacks accelerated to $856M
• Forward P/E of 19.7 against 46.5% operating margins, 31.7% net margins, $6.26B free cash flow, and 0.42 beta reflects buying a best-in-class compounder at a discount
• PEG of 2.54 is elevated for hypergrowth but appropriate for a serial compounder returning 100%+ of FCF to shareholders
• Conservative analyst's plan to trim below $270 into $261-262 support is poor execution — selling weakness after a bounce from $263 to $275
• 200 SMA reclaim historically leads to multi-month advances ~70% of the time over multi-decade sample; selling into this is not asymmetric risk-reward
• ATR of 5.73 means trader-proposed stop at $296 gives ~3.5x ATR of adverse move; not tight risk management, more of a trailing re-evaluation trigger
• Technical report framed bounce as 'counter-trend inside larger bearish regime' — qualified hold with bullish near-term edge, not a bullish call
• 2.71% dividend yield too valuable to sacrifice; brand moat too durable; 8% recession odds and disinflation trend supportive of defensive quality
• Two consecutive US comp misses are material concern warranting action, but management's $856M buyback signals conviction that current price is wrong

→ vs aggressive: Trader's plan oversells — 60-70% trim ignores that MACD crossover and RSI recovery to 55 are real signals; technical report called it neutral-tactical-bullish, not bearish

→ vs aggressive: Third tranche at $295-296 sells into a confirmed 200 SMA reclaim, which historically has ~70% success rate for sustained advances — selling into momentum shift contradicts 'surgical' framing

→ vs aggressive: Stop at $296 gives ~3.5x ATR ($20) of adverse move before cutting — that's not a tight stop, it's a trailing re-evaluation trigger

→ vs conservative: Counter-proposal to trim at $261-262 means selling weakness after watching recovery from $263 to $275 — locking in losses on a stock that put in a higher low and reclaimed 10 EMA and 50 SMA

→ vs conservative: Dismissal of medium-term trend concerns ignores that 50 SMA collapse and 200 SMA slope are dominant forces, not noise; technical report explicitly framed this as 'counter-trend bounce inside larger bearish regime'